SANDOZ RISEDRONATE TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE)

Pieejams no:

SANDOZ CANADA INCORPORATED

ATĶ kods:

M05BA07

SNN (starptautisko nepatentēto nosaukumu):

RISEDRONIC ACID

Deva:

35MG

Zāļu forma:

TABLET

Kompozīcija:

RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

BONE RESORPTION INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0135301003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2010-07-28

Produkta apraksts

______________________________________________________________________________________________
_
_ Sandoz Risedronate (risedronate sodium) Page 1 of 40 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SANDOZ RISEDRONATE
Risedronate Sodium (as the hemi-pentahydrate) Tablets
Tablets, 35 mg, oral
Bisphosphonates
(ATC Code: M05BA07)
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, QC
J4B 1E6
Date of Initial Authorization:
July 28, 2010
Date of Revision:
February 22, 2023
Submission Control Number: 267804
______________________________________________________________________________________________
_
_ Sandoz Risedronate (risedronate sodium) Page 2 of 40 _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
02/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
02/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS...................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Do